MACSF

COMMUNIQUÉS West-GlobeNewswire

Virbac : Déclaration d'actions et de droits de vote 06/2025
04/07/2025
DECLARATION D’ACTIONS ET DE DROITS DE VOTE Informations relatives au nombre total de droits de vote et au nombre d’actions composant le capital (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) [...]
Virbac : Declaration of the number of shares and voting rights 06/2025
04/07/2025
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial [...]
Immuthera’s Scientific Advisory Board: World-Leading Expertise Driving Next-Generation Diabetes and Immunotherapy Solutions
04/07/2025
Immuthera’s Scientific Advisory Board: World-Leading Expertise Driving Next-Generation Diabetes and Immunotherapy Solutions Distinguished experts Dr. Jay Skyler, Dr. Desmond Schatz, and Dr. Lawrence Steinman have joined [...]
Orion publishes Half-Year Financial Report for January–June 2025 and holds a webcast on 18 July 2025
04/07/2025
ORION CORPORATION PRESS RELEASE 4 JULY 2025 at 09.00 EEST Orion publishes Half-Year Financial Report for January–June 2025 and holds a webcast on 18 July 2025 Orion will publish Half-Year Financial Report for January– [...]
Strüngmann Award Honors Araris Biotech Founding Team as 2025 Winner
04/07/2025
The expert jury selected Dragan Grabulovski, Ph.D., Philipp Spycher, Ph.D., and Isabella Attinger-Toller, Ph.D. of Araris Biotech, from a group of outstanding life science entrepreneurs The founding team is developing a [...]
AB Science : Le masitinib reçoit l'autorisation de la FDA et de l'EMA pour l’etude confirmatoire de phase 3 dans le cancer de la prostate métastatique hormono-resistant
04/07/2025
COMMUNIQUÉ DE PRESSE LE MASITINIB REÇOIT L'AUTORISATION DE LA FDA ET DE L'EMA POUR L’ETUDE CONFIRMATOIRE DE PHASE 3 DANS LE CANCER DE LA PROSTATE MÉTASTATIQUE HORMONO-RESISTANT, AVEC UNE SÉLECTION DES PATIENTS BASÉE SUR [...]
AB Science: Masitinib receives FDA and EMA authorization for confirmatory phase 3 trial in metastatic castrate-resistant prostate cancer
04/07/2025
PRESS RELEASE MASITINIB RECEIVES FDA AND EMA AUTHORIZATION FOR CONFIRMATORY PHASE 3 TRIAL IN METASTATIC CASTRATE-RESISTANT PROSTATE CANCER, WITH BIOMARKER-DRIVEN PATIENT SELECTION TARGETING POPULATION MOST LIKELY TO [...]
Nxera Pharma to Receive US$4.8 Million in Milestone Payments Following Centessa’s Initiation of Clinical Development of ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist
04/07/2025
Tokyo, Japan and Cambridge, UK, 4 July 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that it will receive US$4.8 million in milestone payments from Centessa Pharmaceuticals pursuant [...]
Notification for the purposes of article 13 of the Luxembourg law of 11 January 2008 on transparency requirements for issuers
04/07/2025
Luxembourg (July 3, 2025) – Alvotech S.A. announces that on June 25, 2025, the proportion of own shares held by Alvotech S.A. reached 6.73%, crossing above the 5% threshold of the total number of voting rights. The [...]
Remote Pharmacy Releases 2025 Availability Update on GLP-1 Weight Loss Solutions and Consumer Interest in Semaglutide & Tirzepatide
04/07/2025
In this 2025 availability update, Remote Pharmacy highlights the expanded access to non-branded GLP-1-based weight management options, including semaglutide and tirzepatide compounds. The release explores the evolving [...]
Monte Rosa Announces Publication in Science of Key Insights that Enable Next Generation Molecular Glue Degrader Medicines
03/07/2025
Monte Rosa’s AI/ML-powered insights dramatically increase targetable protein space for molecular glue degraders, unlocking new opportunities to address previously undruggable therapeutic targets BOSTON, July 03, 2025 ( [...]
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/07/2025
WESTLAKE VILLAGE, Calif., July 03, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, [...]
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/07/2025
BRISBANE, Calif., July 03, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today [...]
Merit Medical Systems To Announce Second Quarter 2025 Results On July 30, 2025
03/07/2025
SOUTH JORDAN, Utah, July 03, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial [...]
Sienna Announces Second Quarter 2025 Results Release Date and Conference Call
03/07/2025
MARKHAM, Ontario, July 03, 2025 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“ Sienna ” or the “ Company ”) (TSX: SIA) announced that it will report its 2025 second quarter results after market close on Tuesday, [...]
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
03/07/2025
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, July 03, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of [...]
Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/07/2025
RESEARCH TRIANGLE PARK, N.C., July 03, 2025 (GLOBE NEWSWIRE) -- Opus Genetics , Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases ( [...]
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/07/2025
BEDFORD, Mass., July 03, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the osteoarthritis pain management and regenerative solutions spaces focused on early intervention [...]
Theratechnologies annoncera ses résultats financiers du deuxième trimestre de l’exercice financier de 2025
03/07/2025
MONTRÉAL, 03 juill. 2025 (GLOBE NEWSWIRE) -- Theratechnologies inc. (« Theratechnologies » ou la « Société ») (TSX : TH) (NASDAQ : THTX), une société biopharmaceutique au stade commercial, annonce aujourd’hui que la [...]

Pages